Business Wire10d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...
Morningstar11d
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and ...
MedPage Today on MSN9d
Taking on Acquired Resistance in EGFR-Mutant NSCLC
The antibody-drug conjugate (ADC) patritumab deruxtecan (HER3-DXd) is a promising treatment for EGFR inhibitor-resistant ...
pharmaphorum4d
AZ and Daiichi's TROP2 ADC shows promise in first-line lung cancer
Patritumab deruxtecan starts phase 3 Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy ...
pharmaphorum7d
BMS bolts on SystImmune bispecific ADC in $8.4bn deal
Patritumab deruxtecan, which is currently leading the anti-HER3 pipeline, has shown efficacy in heavily pre-treated patients with EGFR-mutated NSCLC previously treated with multiple EGFR ...
Seeking Alpha15d
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
and patritumab deruxtecan - have delivered promising data in lung cancer). There is also a promising late-stage RSV vaccine candidate, cardiovascular drug MK5475, and four immunology drugs ...